AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00987233 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It is to be self-administered; the dosing regimen will be 2 sprays (actuations) into each nostril, once daily. This is the dosing regimen during placebo lead-in and randomized treatment phases. Each actuation of active treatment is equivalent to 55 ug of triamcinolone acetonide, for a total daily dose of 220ug triamcinolone acetonide per day.
Study NCT06107400 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RM-004
Description: Intravenous infusion of gene-edited CD34+autologous hematopoietic stem cells (RM-004) after myeloablative conditioning with busulfan.
Study NCT05298696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol
Description: Cilostazol 100 mg twice daily
Study NCT05298696 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice daily
Study NCT05562024 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T cell injection targeting B7-H3 chimeric antigen receptor
Description: The subjects will be administered once.
Study NCT05086289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3526318
Description: Administered orally
Study NCT05086289 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT05351814 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: While the patients will be exercised with a physiotherapist 1 day a week, the treatment will be followed as a home exercise program 2 days a week.
Study NCT05351814 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: While the patients will be exercised with a physiotherapist 1 day a week, the treatment will be followed as a home exercise program 2 days a week.
Study NCT05695872 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: subtarsal approach
Description: surgical approach
Study NCT05695872 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional transconjunctival approach
Description: surgical approach
Study NCT05695872 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transconjunctival approach with Y- modification
Description: surgical approach
Study NCT04799613 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: walking speed
Description: walking speed (normal speed vs. fast speed). fast speed was 25% faster than normal speed
Study NCT04799613 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: visual loading
Description: visual loading (walking through narrow pathway using VR)
Study NCT04799613 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dual task
Description: dual task (serial subtraction using VR)
Study NCT04799613 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: best side reduction
Description: best side reduction (split belt mode, the speed of best side was reduced by 25% compared to the other side)
Study NCT05173597 — intervention group
Intervention type: DRUG
Intervention: Follitropin delta
Description: REKOVELLE® (follitropin delta), solution for injection - delivered with an injection pen, ATC code G03GA10, is a recombinant human FSH approved for the controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies such as an in vitro fertilisation or intracytoplasmic sperm injection cycle.
Study NCT05876923 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study NCT05253274 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Glasses
Description: In addition to the routine practice of the emergency service, the virtual reality (VR) group will watch a video with VR glasses during the emergency surgical intervention under local anesthesia. Before the emergency surgery, the patients will be asked to wear a VR glasses compatible with mobile phones with android operating system and a headset that minimizes sound loss. Patients will be shown their preferred 3D licensed video software with relaxing music in the background. VR glasses will be put on the patients before starting the emergency surgical procedure under local anesthesia and applied until the procedure was completed. Patients will be asked to refill the The State Anxiety Inventory at the end of the emergency surgical intervention. At the same time, blood pressure, heart rate, respiratory rate, SpO2 values will be monitored on a portable monitor.
Study NCT05667636 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: salvage SBRT
Description: steretactic body radiation therapy in the setting of salvage radiotherapy for prostate cancer
Study NCT05876923 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study NCT05876923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary Exercise Testing
Description: Undergo CPET
Study NCT05876923 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiopulmonary Exercise Testing
Description: Undergo CPET
Study NCT05876923 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual X-ray Absorptiometry
Description: Undergo DEXA scan
Study NCT05876923 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dual X-ray Absorptiometry
Description: Undergo DEXA scan
Study NCT05876923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies
Study NCT05876923 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Health Record Review
Description: Ancillary studies
Study NCT05876923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo aerobic based training program
Study NCT05876923 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: Undergo aerobic based training program
Study NCT05876923 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Examination
Description: Undergo measurement of height/weight and vital signs
Study NCT05876923 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical Examination
Description: Undergo measurement of height/weight and vital signs
Study NCT04836819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocain
Description: IV lidocaine infusion (2 mg/kg/h) will be initiated after anesthesia induction and decrease the dosage to 1 mg/kg/h at the end of surgery. The infusion will continue until 12 hours after the operation.1 g paracetamol, 100 mg tramadol, 100 mg ketoprofen, and 4 mg dexamethasone will be administered to all patients pre-emptively. Granisetron (3 mg) will be administered 30 minutes before the end of surgery. In the postoperative period, i.v. Paracetamol will be administered at 8-hour intervals and 25-50 mg meperidine i.m. (maximum dose 200 mg) as rescue analgesia when requested by the patient and if VAS>4.
Study NCT04836819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: IV ketamine infusion (0.5 mg/kg/h) will be initiated after anesthesia induction and decrease the dosage to 0.3 mg/kg/h at the end of surgery. The infusion will continue until 12 hours after the operation.1 g paracetamol, 100 mg tramadol, 100 mg ketoprofen, and 4 mg dexamethasone will be administered to all patients pre-emptively. Granisetron (3 mg) will be administered 30 minutes before the end of surgery. In the postoperative period, i.v. Paracetamol will be administered at 8-hour intervals and 25-50 mg meperidine i.m. (maximum dose 200 mg) as rescue analgesia when requested by the patient and if VAS>4.
Study NCT04836819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: IV dexmedetomidine infusion (0.5 mg/kg/h) will be initiated after anesthesia induction and decrease the dosage to 0.3 mg/kg/h at the end of surgery. The infusion will continue until 12 hours after the operation.1 g paracetamol, 100 mg tramadol, 100 mg ketoprofen, and 4 mg dexamethasone will be administered to all patients pre-emptively. Granisetron (3 mg) will be administered 30 minutes before the end of surgery. In the postoperative period, i.v. Paracetamol will be administered at 8-hour intervals and 25-50 mg meperidine i.m. (maximum dose 200 mg) as rescue analgesia when requested by the patient and if VAS>4.
Study NCT05876923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05876923 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05876923 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spirometry
Description: Undergo spirometry
Study NCT05626023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human TH-SC01 cell injection
Description: Single injection of human TH-SC01 cell injection
Study NCT05409326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQH2722 injection
Description: TQH2722 is a fully human monoclonal antibody directed against the interleukin (IL)-4 receptor α subunit (IL-4Rα) of IL-4 heterodimeric type I and type II receptors that mediate IL-4/IL-13 signaling through this pathway. Blockade of these receptors broadly suppresses type 2 inflammation associated with atopic/allergic diseases.
Study NCT05876923 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spirometry
Description: Undergo spirometry
Study NCT05876923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Performance Testing
Description: Undergo muscular strength and functional endurance measurements
Study NCT05876923 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Performance Testing
Description: Undergo muscular strength and functional endurance measurements
Study NCT05876923 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care
Study NCT05427695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus sakei proBio65
Description: Lanto Sinus probiotic Lactobacillus sakei is a currently available over the counter supplement from the common source kimchi and produced in South Korea. Patients will be instructed to mix 1 packet with lukewarm distilled or boiled water in 240mL NeilMed® sinus rinse bottle.
Study NCT05427695 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic Saline Solution
Description: Saline sinus irrigations (SAL group): NeilMed® Isotonic Sinus Rinse™ is marketed as a saline sinus irrigation formula. Subjects will be given instructions to mix one unlabeled packet (containing NeilMed® premixed buffered salt powder) with lukewarm distilled or boiled water in 240mL NeilMed® sinus rinse bottle.
Study NCT04705116 — intervention group
Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine
Description: At least one dose of a COVID-19 vaccine.
Study NCT05134649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Description: Intramuscular Injection
Study NCT05356689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mechanical traction
Description: Group A: This group will get 3-dimensional lumbar traction on multi-dimensional traction bed spine MT. Group B: This group will get 2-dimensional lumbar traction on 2-dimensional traction bed. Common Treatment: Hot pack (for 10 minutes), and US 1mhz for 7 minutes, Mackenzie exercises and cold pack will applied for 15 minutes after traction.
Study NCT05069649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergoferon
Description: Tablet for oral use.
Study NCT05483621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta-hCG
Description: Treatment of spermatogenesis
Study NCT05483621 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Beta-hCG
Description: Treatment of spermatogenesis
Study NCT06394518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2092 for injection
Description: The study had 3 dose groups, a 200 mg single dose group (low-dose group), a 300 mg single and multiple dose continuous dose group (medium-dose group), and 400 mg single dose group (high-dose group)
Study NCT06394518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: The placebo for TNP-2092 active drug
Study NCT06394518 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo for TNP-2092 active drug
Study NCT05784337 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mi-thos® Transcatheter Mitral Valve Replacement System
Description: Transcatheter Mitral Valve Replacement
Study NCT05053997 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NAVIGATE
Description: Patients' symptoms are systematically monitored by use of bi-weekly patient reported outcomes and nurse navigators will initiate appropriate actions in terms of medical treatment or guidance of self-management strategies. Nurse navigators will motivate and support patients in health behavior changes and in selfmanaging their treatment and symptoms, and, if relevant, refer to existing rehabilitation services at the hospital or at the local rehabilitation center. Physiotherapists will supervise a training program aimed at improving patients' physical function and thus potentially surgery and overall treatment adherence and outcomes.
Study NCT05015166 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Internet delivered self-help program with therapist support
Description: During 8 weeks of treatment participants are taught how emotional conflicts may underlie and perpetuate symptoms of social anxiety. They are also taught how to observe their own anxiety and emotional avoidance (i.e. defenses) and how to gradually approach previously warded off feelings. The final part of the program contains material on how one may express previously warded off emotions to improve important relationships. The treatment program consists of text, videos and a series of experiential exercises which a therapist gives feedback on.
Study NCT06100458 — intervention group
Intervention type: OTHER
Intervention: Skin and leakage protocol
Description: The skin and leakage protocol have been developed by the sponsor with the aim to offer a tool that can aid care providers in identifying problems in continence care and follow up the effect of any care interventions to remedy these problems. The protocol is a digital diary tool that tracks both the instances of urine leaking out of an absorbing incontinence product onto clothes and bedsheets, and any apparent skin changes in the area covered by the product. The protocol is in clinical use at the care homes were the subjects are residing.
Study NCT05069649 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet for oral use.
Study NCT06165991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine, Bupivacaine
Description: 1.33% (liposomal bupivacaine, LB) 20mL thoracic paravertebral nerve block complex PCIA;~1.33% (liposomal bupivacaine, LB) 20mL thoracic paravertebral nerve block combined with drainage tube analgesia technique combined with PCIA
Study NCT06165991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine, Bupivacaine
Description: 1.33% (liposomal bupivacaine, LB) 20mL thoracic paravertebral nerve block complex PCIA;~1.33% (liposomal bupivacaine, LB) 20mL thoracic paravertebral nerve block combined with drainage tube analgesia technique combined with PCIA
Study NCT05409326 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match TQH2722
Description: TQH2722 is a fully human monoclonal antibody directed against the interleukin (IL)-4 receptor α subunit (IL-4Rα) of IL-4 heterodimeric type I and type II receptors that mediate IL-4/IL-13 signaling through this pathway. Blockade of these receptors broadly suppresses type 2 inflammation associated with atopic/allergic diseases.
Study NCT04850599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV
Study NCT04850599 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Given IV
Study NCT04850599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Given PO
Study NCT06396936 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calisthenic exercise program
Description: Calisthenic exercises to be applied in our study; These are exercises that are performed by creating resistance only with your body weight, without the need for any equipment or gym.
Study NCT06280209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 351
Description: Anti-sense Oligonucleotide BMN 351 will be administered intravenously.
Study NCT06564493 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: TBI
Description: The total dose of TBI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
Study NCT06564493 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TMLI
Description: The total dose of TMLI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
Study NCT06564493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: The total dose of cyclophosphamide is 120 mg/kg, administered over 2 days on days -4 and -3.
Study NCT06564493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: The total dose of cyclophosphamide is 120 mg/kg, administered over 2 days on days -4 and -3.
Study NCT04383262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosamprenavir Calcium
Description: A repurposing approach, prospective, placebo-controlled clinical trial of FOS-SA (used at 1,400 mg fosamprenavir calcium and 24.5 mg sodium alginate, twice daily) for 12 weeks in medically refractory patients with clinically diagnosed moderate/severe LPR (RSI > 13, RFS > 7 and MII-pH confirmed laryngeal reflux event\[s\]).
Study NCT04383262 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Alginate: 1,399 mg microcrystalline cellulose and 24.5 mg sodium alginate morning and night.
Study NCT05893511 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic ultrasound-guided gallbladder drainage
Description: Prior to the procedure, the patients would be kept fasted for 6 hours and antibiotics would be commenced (2nd generation cephalosporin or equivalent). EUS-GBD would be performed by either the conventional or direct method. A 10mm stent system would be used if the largest gallstone is smaller than 10mm in size and a 16mm stent is used if the largest gallstone is larger than 10mm. The distal flange of the stent would be deployed under EUS guidance, followed by deployment of the proximal flange under endoscopic guidance. Once deployed, the gallbladder is completely emptied by suction and irrigation until the effluent through the stent is clean. The need of inserting an additional double pigtail plastic stent through the LAMS would be decided by the endosonographer. A course of antibiotics will be continued for 7 days after the procedure .
Study NCT05893511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics first
Description: Patients randomized to antibiotics first would be given intravenous antibiotics 2nd generation cephalosporin or equivalent). Antibiotics would first be given parenterally and then switched to oral form when patient can tolerate diet or when sepsis subside. It will be continued for at least a total of 7 days.
Study NCT06458556 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment with Morpheus
Description: Radiofrequency device treatment
Study NCT04923711 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise prescription
Description: Exercise Intensity： Low-risk patients: the lower of 60-69% reserve heart rate or the heart rate at the anaerobic threshold.~Moderate-risk or high-risk patients: the lower of 50-59% reserve heart rate or the heart rate at the anaerobic threshold.
Study NCT04923711 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity exercise prescription
Description: Exercise Intensity： Low-risk patients: the lower of 70-85% reserve heart rate or the heart rate at the anaerobic threshold.~Moderate-risk or high-risk patients: the lower of 60-70% reserve heart rate or the heart rate at the anaerobic threshold.
Study NCT05016622 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine
Description: Administer an additional dose of the BNT162b2 mRNA vaccine to patients with cancer who have a negative SARS-CoV-2 Spike IgG at least 14 days after 2 doses of the mRNA vaccines (BNT162b2/mRNA-1273) or 28 days after the adenoviral based Ad26CoV2.S vaccine.
Study NCT06446141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic technique
Description: Patients will be positioned in a supine position. Osteopathic technique will consist of supoccibital release, soft tissue release of thoracic outlet, mobilization of cervical facet joints, stretching of scalene anterior, scalene medius, upper trapezius, and levator scapula, pectorals major and minor. Subsequently, cost vertebral and cost transverse joint mobilizations will be applied using rib elevation. Then, manipulation of the vertebrae the levels between C6 and T1 will be applied using thrust mobilization technique. Afterwards, mobilization of the first rib will be applied. Finally, mobilization of the upper cervical spine will be performed.